Weaver Labs.New technology described as the “first of its kind in the UK” is set to revolutionise live football matches, according to scientists.
The…

Weaver Labs.New technology described as the “first of its kind in the UK” is set to revolutionise live football matches, according to scientists.
The…

Paul FaulknerLocal Democracy Reporting Service
GoogleNuclear fuel used to power homes is set to be recycled to help develop life-saving therapies for hard-to-treat cancers in a pioneering new project.
The UK National Nuclear Laboratory (UKNLL) in Salwick, Preston, and Medicines Discovery Catapult, have been awarded £9.9m by the government to produce cutting-edge treatments that have fewer side effects.
The process involves harvesting nuclear material that has been used to power homes, which is then recycled to provide radiation therapy that targets cancer cells with minimal damage to healthy tissue.
Science and Technology Secretary Liz Kendall hopes Targeted Alpha Therapy “could give cancer patients more priceless time with their loved ones”.
The UKNLL said the amount of spent nuclear fuel available in the UK means the specialist treatment could benefit thousands of patients nationwide and help position the UK as “a leader in precision cancer medicines”.
A tiny amount of the fuel known as lead-212 is extracted through a series of chemical reactions, equivalent to taking a single drop of water from an Olympic-sized swimming pool.
An even smaller amount of lead-212 – a radionuclide – is then taken from that sample, which, when developed under the right conditions by scientists could treat thousands of individuals.
Radionuclides are already used worldwide for medical scans to diagnose cancer and other conditions.
Julianne Antrobus, UKNNL chief executive, said: “Through access to the UK’s sovereign supply of lead-212, we have a truly unique opportunity to transform our nuclear expertise into life-saving cancer treatments.
“By developing the infrastructure and processes… we’re not only advancing precision nuclear medicine but also reinforcing the UK’s position as a world leader in both nuclear science and healthcare innovation.
“This investment will help us deliver treatments that could transform outcomes for patients with previously untreatable cancers, both here in the UK and globally.”
The government is investing £9.9m from the Innovate UK Sustainable Medicines Manufacturing Innovation Programme, while industry will plough in a further £8.9m.
Kendall added: “Almost 3.5 million people in the UK are living with cancer but scientific breakthroughs are giving hope to more of them and their families.
“It’s incredible to think we could turn used nuclear fuel into cutting-edge cancer treatments but that is exactly what British scientific brilliance is making possible.”

Hong Kong
—
The Hong Kong residential towers engulfed by smoke and flames on Wednesday were surrounded by an ancient construction material familiar to anyone who’s spent time in…

Soybean oil, the most widely consumed cooking oil in the United States and a staple of processed foods, contributes to obesity, at least in mice, through a mechanism scientists are now beginning to understand.
In an experiment…

Microsoft has launched Fara-7B, its first small language model built to operate a computer the way a person does. The company claims the 7-billion-parameter model matches or beats larger agentic systems on live web tasks while running…

Evie Lake,North East and Cumbriaand
Matt Bailey,BBC Radio Newcastle
Ellen DixonA heavy metal band is appealing for unused and unloved instruments so they can be donated to families in time…

New findings indicate that people who do not treat obstructive sleep apnea face a greater likelihood of developing Parkinson’s disease. Using continuous positive airway pressure, or CPAP, can help lower that risk by improving sleep quality and…

New findings indicate that people who do not treat obstructive sleep apnea face a greater likelihood of developing Parkinson’s disease. Using continuous positive airway pressure, or CPAP, can help lower that risk by improving sleep quality and…

Ever wondered if SAP is really offering good value, or if there is something under the surface investors are missing?
After a remarkable multi-year run, with the stock up over 100% in the last three years, SAP shares have dipped 12.2% over the past month and are down 13.4% year-to-date. This has sparked renewed debate about what comes next.
Recent headlines show growing interest in SAP’s AI integrations and expanded global partnerships. These factors have kept sentiment buoyant even amid the recent price pullback. Industry analysts are watching closely to see if these initiatives translate into sustained competitive advantages.
Based on Simply Wall St’s valuation checks, SAP earns a score of 3 out of 6 for undervaluation, placing it right in the middle of the pack. Next, let’s dive deeper into the valuation process itself. Stay tuned as we also share a smarter way to look at value towards the end of the article.
SAP delivered -5.3% returns over the last year. See how this stacks up to the rest of the Software industry.
The Discounted Cash Flow (DCF) model projects SAP’s future cash flows and then discounts them back to today’s value, providing an estimate of the company’s value. This method uses both analyst forecasts and data-driven extrapolations to look ahead, helping investors understand the long-term earning potential of the business.
SAP’s latest reported Free Cash Flow is just over €6.4 Billion. Analysts expect this figure to increase steadily, with projections reaching about €9.6 Billion by 2027. Using Simply Wall St’s methodology, longer-term estimates are developed, forecasting Free Cash Flow to rise beyond €16.9 Billion by 2035. These projections are intended to offer a reliable view of SAP’s earnings profile over the coming decade.
Based on these cash flow projections, the DCF model calculates SAP’s intrinsic value at €253.82 per share. This is nearly 18.6% higher than its current price, suggesting the market may be underestimating SAP’s future cash generation potential and ongoing investment in AI and global partnerships.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests SAP is undervalued by 18.6%. Track this in your watchlist or portfolio, or discover 926 more undervalued stocks based on cash flows.
Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for SAP.
For established, profitable companies like SAP, the Price-to-Earnings (PE) ratio is often a key metric for valuation. It shows how much investors are willing to pay today for a Euro of SAP’s current earnings, making it a particularly meaningful gauge when the business is generating consistent profits.